pertuzumab
pertuzumab: sourced relationships with 1 company · 34 clinical trials tracked.
pertuzumab evidence translation
What we can confirm
34 tracked trials
What it means
What to watch
Prepared research question
How could pertuzumab → OGN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Organon & Co. (OGN) pertuzumab in combination with trastuzumab and chemotherapy … | — |
Clinical Trial Registry Records (34)showing 10 most recent
Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy
Primary endpoint: Overall survival (OS) (Cohort A)
An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.
Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
A RANDOMIZED, DOUBLE-BLIND, INTRAVENOUS SINGLE-DOSE, PARALLEL-CONTROLLED PHASE I CLINICAL STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY, AND IMMUNOGENICITY OF PERTUZUMAB INJECTION BEFORE AND AFTER PROCESS CHANGE IN HEALTHY MALE PARTICIPANTS
Primary endpoint: AUC0-inf
A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)
Primary endpoint: Progression-free Survival (PFS) Rate at 24 Months
A Randomized Controlled Phase III Clinical Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Primary endpoint: Progression-free survival (PFS)
EUREKA Study: Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer Using ctDNA and HARPS Biomarker Assay
Primary endpoint: outcomes that correspond directly to the objective(s)
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Primary endpoint: Number of participants with pCR
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
Primary endpoint: Recurrence-free survival (RFS)
Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors
Primary endpoint: Number/incidence and percentage of subjects with adverse events.
HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer
Primary endpoint: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Frequently asked questions
Which companies have sourced relationships with pertuzumab?
pertuzumab has dated SEC/FDA relationship records for Organon & Co..
How many clinical trials involve pertuzumab?
BioSniper tracks 34 clinical trials involving pertuzumab.